IRONWOOD PHARMACEUTICALS, INC. Accrued Liabilities, Current
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Accrued Liabilities, Current of $38.30 million as of 2016-12-31, per its 10-K filed 2017-02-22.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2017-02-22
- 2016-12-31: Accrued Liabilities, Current $38.30M.
- 2016-09-30: Accrued Liabilities, Current $29.05M.
- 2016-06-30: Accrued Liabilities, Current $20.60M.
- 2015-12-31: Accrued Liabilities, Current $23.30M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2016-12-31 | $38.30M 10-K · filed 2017-02-22 |
| 2016-09-30 | $29.05M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $20.60M 10-Q · filed 2016-08-08 |
| 2015-12-31 | $23.30M 10-K · filed 2017-02-22 |
| 2015-06-30 | $18.95M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $18.73M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $22.61M 10-K · filed 2016-02-19 |
| 2014-09-30 | $26.88M 10-Q · filed 2014-11-05 |
| 2014-06-30 | $19.05M 10-Q · filed 2014-08-05 |
| 2014-03-31 | $17.41M 10-Q · filed 2014-04-29 |
| 2013-12-31 | $18.44M 10-K · filed 2015-02-18 |
| 2013-09-30 | $18.80M 10-Q · filed 2013-10-28 |
| 2013-06-30 | $17.12M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $20.46M 10-Q · filed 2013-04-23 |
| 2012-12-31 | $21.17M 10-K · filed 2014-02-07 |
| 2012-09-30 | $16.69M 10-Q · filed 2012-11-06 |
| 2012-06-30 | $13.22M 10-Q · filed 2012-08-07 |
| 2012-03-31 | $11.60M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $11.12M 10-K · filed 2013-02-21 |
| 2011-09-30 | $9.25M 10-Q · filed 2011-11-09 |
| 2011-06-30 | $6.65M 10-Q · filed 2011-08-12 |
| 2010-12-31 | $8.94M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |